SCHEMBL1779308

SCHEMBL1779308

CC(C)(C)OC(=O)N1CCC2(CC1)CCN(c1ccc3ccccc3c1)CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 7/20 0.55
CYP3A4 P08684 6/20 0.55
ALDH1A1 P00352 6/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
TSHR P16473 3/20 0.55
TP53 P04637 1/20 0.55
USP2 O75604 5/20 0.54
HSD17B10 Q99714 4/20 0.54
CYP1A2 P05177 4/20 0.54
CYP11B2 P19099 1/20 0.53
CYP2C19 P33261 3/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PDK2 Q15119 1/20 0.51
GPR119 Q8TDV5 4/20 0.50
CYP2C9 P11712 3/20 0.50
CYP2D6 P10635 2/20 0.50
HIF1A Q16665 2/20 0.50
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18831899 0.83 USP2 (0.58) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL21946732 0.80 MAPK1 (0.54) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL485724 0.80 MAPK1 (0.54) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL26101978 0.80 MAPK1 (0.54) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL1779228 0.80 SMN1; SMN2 (0.57) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL24793978 0.80 ALDH1A1 (0.48) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL29709652 0.80 ALDH1A1 (0.48) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL484899 0.79 CYP11B2 (0.60) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL31091690 0.79 HDAC2 (0.52) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR
SCHEMBL30831047 0.79 GPR119 (0.50) MAPK1CYP3A4ALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943630-B2 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-05-17 US disclosed
EP-1917264-B1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors ANIONA APS (DK) 2009-04-30 US disclosed
EP-1917264-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2008-05-07 EP disclosed
WO-2007000463-A1 NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111841-A1 Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC6A2, SLC6A3 MAPK1 3840/4885CYP3A4 664/4885ALDH1A1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.